Foundation Announces $37.7 Million Expanded Collaboration with EPIX Pharmaceuticals
April 7, 2008
Cystic Fibrosis Foundation Therapeutics, Inc., a non-profit affiliate of the CF Foundation, announced today an expanded collaboration with EPIX Pharmaceuticals, Inc., to develop drugs for CF worth up $37.7 million.
The Foundation extended the collaboration following EPIX’s successful development of a computerized 3-D model of the full-length Cystic Fibrosis Transmembrane conductance Regulator (CFTR), the key protein associated with cystic fibrosis. The new agreement with EPIX, a company focused on discovering and developing novel therapeutics, brings the total size of the collaboration to more than $50 million.
EPIX scientists are now using the CFTR model to identify sites within the Delta F508 mutation of CFTR—the most common mutation in CF patients—which may be good targets for treatment. The Foundation is working with EPIX to discover drug candidates that may work on those sites and possibly restore function to the mutated CFTR protein.
“This is an expansion of a very important and productive alliance to develop new drugs to treat the core defect in cystic fibrosis,” said Robert J. Beall, Ph.D., president and chief executive officer of the Cystic Fibrosis Foundation. “EPIX has exceeded our expectations to date, and we look forward to their efforts to use unique structure-based technologies to identify molecules that may correct the faulty protein in CF—and potentially create new therapies for CF.”
Read the full press release.